DNLI Stock Analysis: Buy, Sell, or Hold?
DNLI - Denali Therapeutics Inc. Common Stock
$18.16
-1.57 (-7.98%)
▼
5d:
-9.97%
30d:
-15.22%
90d:
+7.33%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Distribution
DNLI is up 4.5% this week, but smart money is buying puts. Top strike: $20 2026-04-17 with 2,902 OI. Put ratio: 67% View Scanner →
Strength: 3.9/10
Get Alerted When DNLI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DNLI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: DNLI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: DNLI is currently trading at $18.16, which is considered oversold relative to its 30-day fair value range of $19.64 to $21.48.
Technical Outlook: Technically, DNLI is in a strong uptrend. The price is currently testing key support at $18.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $36.14 (+99.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DNLI is in a strong uptrend. The price is currently testing key support at $18.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $36.14 (+99.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$19.64 -
$21.48
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.0%)
- BULLISH: Trading 99.0% below Wall St target ($36.14)
- CAUTION: Recommendation downgraded due to -10.0% 5-day decline
Fair Price Analysis
30-Day Fair Range
$19.64 -
$21.48
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$18.57
Resistance Level
$23.46
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.41
Wall Street Target
$36.14
(+99.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: March 30, 2026 8:51 AM ET
Data refreshes hourly during market hours. Next update: 9:51 AM
Data refreshes hourly during market hours. Next update: 9:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNLI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Alexander O Schuth
SELL
17218 shares
2026-01-06
Ryan J Watts
SELL
35198 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 63 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 65 BUY |
